


Carbazochrome sodium sulfonate

Chemical Properties

CAS No. :	51460-26-5
Formula:	C10H11N4NaO5S
Molecular Weight:	322.03
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Carbazochrome sodium sulfonate (AC-17) is an antihemorrhagic agent used for treating hemorrhoids.
Targets(IC50)	Adrenergic Receptor
In vitro	Administering 10 mg/kg of Carbazochrome significantly inhibited the reduction of arterial oxygen levels. Additionally, at the same dosage, Carbazochrome reversed the iodocetate-induced increase in vascular permeability in rats in a dose-dependent manner.
In vivo	Carbazochrome at concentrations of 0.1-1 M attenuates concentration-dependent synthesis of [(3)H]myo-inositol and [(3)H]-inositol induced by bradykinin and thrombin. It also counteracts the functional impairment caused by trypsin, thrombin, and bradykinin, with ionophores like ionomycin, A23187, or phorbol 12-myristate 13-acetate enhancing this effect without affecting endothelial permeability. In human umbilical vein endothelial cells, carbazochrome significantly reduces the ratio of t-PA antigen in the culture medium without notably affecting the PAI-1 antigen ratio. It reverses trypsin-induced actin stress fiber formation and disrupts VE-cadherin in monolayers of porcine aortic endothelial cells. Additionally, in cultured bovine vascular endothelial cells, carbazochrome distinctly inhibits hyperpermeability induced by trypsin, thrombin, and protease-activated receptor 2 agonist peptides.

Solubility Information

Solubility	Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 12 mg/mL (37.26 mM),Sonication is recommended. H2O: 3 mg/mL (9.32 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.21 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.1053 mL	15.5265 mL	31.053 mL
5 mM	0.6211 mL	3.1053 mL	6.2106 mL
10 mM	0.3105 mL	1.5527 mL	3.1053 mL
50 mM	0.0621 mL	0.3105 mL	0.6211 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Sendo T, et al. Naunyn Schmiedebergs Arch Pharmacol, 2003, 368(3), 175-180.

Sendo T, et al. Eur J Pharmacol, 2002, 450(2), 203-208.

Matsumoto Y, et al. Blood Coagul Fibrinolysis, 1995, 6(3), 233-238.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481